BioSpace News Archive

The FDA has a few target action dates for the end of the month, although PDUFA dates can sometimes seem like a moving target.

As the American Society of Gene & Cell Therapy’s 25th Annual Meeting wraps up, a host of life science companies touted their research and products. BioSpace looks at some of them.

Zealand Pharma shared positive top-line results for its second Phase III clinical trial of its congenital hyperinsulinism (CHI) drug, dasiglucagon, in pediatric patients.

According to researchers at the Universite Sorbonne Paris Nord, Universite Paris-Saclay, ants can be trained to sniff out the specific odors associated with certain cancers.

Germany-based Evotec AG forged its third partnership in May, a deal with Spain’s Almirall S.A. to develop new therapeutics for severe diseases of the skin.

Maxwell Serowoky has observed an increase in Sonic Hedgehog (Shh) gene activity during rib bone recovery, expanding the gene’s function beyond the known role of embryogenesis.

Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to XMT-2056.

Anavex Life Sciences to Present at the H. C. Wainwright Global Investment Conference 2022.

Shockwave Medical, Inc., a pioneer in the development of Intravascular Lithotripsy to treat severely calcified cardiovascular disease, announced new data confirming excellent one-year outcomes with coronary IVL in both women and men.

Ocuphire Pharma, Inc. today announced positive topline results from the LYNX-1 Phase 3 pivotal clinical trial investigating its product candidate Nyxol® for night (or dim light) vision disturbances (NVD).